X-linked hypophosphatemia: Understanding and management

E. A. Imel, Munro Peacock

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

X-Linked hypophosphatemia (XLH) is a disease of phosphorus metabolism resulting from mutations in PHEX on the X chromosome that encodes for phosphate-regulating neutral endopeptidase, X-linked (PEX), a membrane-bound metalloendopeptidase that is predominantly expressed in bone and teeth. The disease manifests in children as rickets, which progresses to osteomalacia in adults. Hypophosphatemia is the primary biochemical disturbance underlying the rickets and osteomalacia. Decreased tubular reabsorption of phosphate, the direct cause of hypophosphatemia, is due to increased plasma fibroblast growth factor 23 (FGF-23) acting on renal tubular sodium/phosphate cotransporters. Three mouse models of XLH have been developed and have greatly helped unravel the pathophysiology in humans and the exploration of new approaches to medical management. Current treatments are unsatisfactory. They do not cure the disease, but only partially relieve some of the skeletal and biochemical abnormalities, and result in several undesirable side effects. New treatments aimed at decreasing plasma FGF-23 activity show significant potential for reversing both the biochemical and rachitic/osteomalacic abnormalities.

Original languageEnglish (US)
Pages (from-to)755-763
Number of pages9
JournalDrugs of the Future
Volume35
Issue number9
DOIs
StatePublished - Sep 1 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'X-linked hypophosphatemia: Understanding and management'. Together they form a unique fingerprint.

Cite this